Quadrature Capital’s Abiomed Inc ABMD Stock Holding History

Quadrature Capital’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,949	Closed	-$1.41M	–	721
2019 Q1	$1.41M	Buy	+4,949	New	+$1.64M	0.12%	178
2018 Q1	–	Sell	-13,032	Closed	-$2.44M	–	797
2017 Q4	$2.44M	Buy	+13,032	New	+$2.43M	0.22%	122
2017 Q1	–	Sell	-4,316	Closed	-$486K	–	920
2016 Q4	$486K	Buy	+4,316	New	+$500K	0.03%	432

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Quadrature Capital's ABMD Position: Q2 2019 in Review

Quadrature Capital sold out of Abiomed Inc (ABMD) in Q2 2019, closing a stake of 4,949 shares — an estimated $1.41M sold.

Quadrature Capital first reported a position in ABMD in Q4 2016 and held it in 3 quarters. The position peaked at $2.44M in Q4 2017. 483 funds tracked by Wall St. Rank hold ABMD as of Q2 2019.

Quadrature Capital reported no remaining Abiomed Inc position as of Q2 2019 after selling out during the quarter.
Quadrature Capital sold 4,949 Abiomed Inc shares in Q2 2019, an estimated $1.41M.
Quadrature Capital first reported a position in Abiomed Inc in Q4 2016 and held it in 3 quarters.
Quadrature Capital's Abiomed Inc position peaked at $2.44M in Q4 2017.
483 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2019.

Based on Quadrature Capital's 13F filing for Q2 2019, filed 14 Aug 2019.